18:52 , Oct 5, 2017 |  BC Innovations  |  Translation in Brief

SSRIs' first responders

Researchers at The Rockefeller University have identified a role for CCK-expressing neurons in initiating responses to SSRIs for depression and manipulated the neurons to recapitulate the drugs' effects. The findings could lead to faster-acting antidepressants...
19:21 , Jul 13, 2017 |  BC Innovations  |  Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...
07:00 , Jun 28, 2012 |  BC Innovations  |  Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program (see "Repurposing pharma compounds"). The compounds provided...
07:00 , Apr 21, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

Approach Summary Licensing status Publication and contact information Imaging Stabilized, cholecystokinin B receptor (CCKBR; CCK2R)-targeting radiopeptide for tumor imaging A CCK2R-targeting radiopeptide could be useful for imaging tumors. Earlier...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Clinical News

BNC210: Phase Ib data

The double-blind, crossover, French Phase Ib BNC210.004 trial in 15 evaluable healthy male volunteers with cholecystokinin tetrapeptide (CCK-4)-induced panic attacks showed that a single dose of oral BNC210 significantly reduced total PSS score and intensity...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Clinical News

BNC210: Phase Ib start

This month, Bionomics will begin a double-blind, placebo-controlled, French Phase Ib trial to evaluate a single dose of oral BNC210 in 22 healthy male volunteers with cholecystokinin tetrapeptide (CCK-4)-induced panic-like symptoms. Bionomics Ltd. (ASX:BNO; OTCBB:BMICY),...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

TT-223: Development discontinued

Transition and partner Eli Lilly discontinued development of TT-223 after a double-blind, placebo-controlled, U.S. Phase Ib trial in about 150 patients showed that the compound in combination with LY2428757, a Phase II pegylated ...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche's Genentech Inc.unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease.1 Nineteen of the 112 candidate cancer genes identified...
07:00 , Mar 22, 2010 |  BioCentury  |  Product Development

Playing turnabout

The dramatic effects of gastric banding surgery on diabetes published two years ago raised the question of whether the procedure could obviate the need for new diabetes drugs. But turnabout is fair play, as researchers...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

TT-223: Phase II data

Data from a double-blind, dose-ranging, U.S. Phase II trial in about 80 patients on background metformin or thiazolidinedione therapy showed that 3 mg once-daily subcutaneous TT-223 met the secondary endpoint of significantly reducing HbA1c from...